Tweet
Clin Infect Dis. 2017 Oct 4. doi: 10.1093/cid/cix869. [Epub ahead of print]
2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States.
Poehling KA1, Caspard H2, Peters TR1, Belongia EA3, Congeni B4, Gaglani M5, Griffin MR6, Irving SA7, Kavathekar PK8, McLean HQ3, Naleway AL7, Ryan K9, Talbot HK6, Ambrose CS2.
Author information
Abstract
Background:
In the 2015-2016 season, quadrivalent live attenuated influenza vaccine (LAIV) and both trivalent and quadrivalent inactivated influenza vaccine (IIV) were available in the United States.
Methods:
This study, conducted according to a test-negative case-control design, enrolled children aged 2-17 years presenting to outpatient settings with fever and respiratory symptoms for <5 days at 8 sites across the United States between November 30, 2015 and April 15, 2016. A nasal swab was obtained for reverse transcriptase-polymerase chain reaction (RT-PCR) testing for influenza, and influenza vaccination was verified in the medical record or vaccine registry. Influenza vaccine effectiveness (VE) was estimated using a logistic regression model.
Results:
Of 1012 children retained for analysis, most children (59%) were unvaccinated, 10% received LAIV, and 31% received IIV. Influenza A (predominantly antigenically similar to the A/California/7/2009 strain) was detected in 14% and influenza B (predominantly a B/Victoria lineage) in 10%. For all influenza, VE was 46% (95% confidence interval [CI], 7-69%) for LAIV and 65% (95% CI, 48-76%) for IIV. VE against influenza A(H1N1)pdm09 was 50% (95% CI, -2% to 75%) for LAIV and 71% (95% CI, 51-82%) for IIV. The odds ratio for vaccine failure with RT-PCR-confirmed A(H1N1)pdm09 was 1.71 (95% CI, 0.78-3.73) in LAIV versus IIV recipients.
Conclusions:
LAIV and IIV demonstrated effectiveness against any influenza among children aged 2-17 years in 2015-2016. When compared to all unvaccinated children, VE against influenza A(H1N1)pdm09 was significant for IIV but not LAIV.
ClinicalTrials.gov identifier:
NCT01997450.
KEYWORDS:
children; influenza; influenza vaccine; vaccine effectiveness
PMID: 29029064 DOI: 10.1093/cid/cix869
2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States.
Poehling KA1, Caspard H2, Peters TR1, Belongia EA3, Congeni B4, Gaglani M5, Griffin MR6, Irving SA7, Kavathekar PK8, McLean HQ3, Naleway AL7, Ryan K9, Talbot HK6, Ambrose CS2.
Author information
Abstract
Background:
In the 2015-2016 season, quadrivalent live attenuated influenza vaccine (LAIV) and both trivalent and quadrivalent inactivated influenza vaccine (IIV) were available in the United States.
Methods:
This study, conducted according to a test-negative case-control design, enrolled children aged 2-17 years presenting to outpatient settings with fever and respiratory symptoms for <5 days at 8 sites across the United States between November 30, 2015 and April 15, 2016. A nasal swab was obtained for reverse transcriptase-polymerase chain reaction (RT-PCR) testing for influenza, and influenza vaccination was verified in the medical record or vaccine registry. Influenza vaccine effectiveness (VE) was estimated using a logistic regression model.
Results:
Of 1012 children retained for analysis, most children (59%) were unvaccinated, 10% received LAIV, and 31% received IIV. Influenza A (predominantly antigenically similar to the A/California/7/2009 strain) was detected in 14% and influenza B (predominantly a B/Victoria lineage) in 10%. For all influenza, VE was 46% (95% confidence interval [CI], 7-69%) for LAIV and 65% (95% CI, 48-76%) for IIV. VE against influenza A(H1N1)pdm09 was 50% (95% CI, -2% to 75%) for LAIV and 71% (95% CI, 51-82%) for IIV. The odds ratio for vaccine failure with RT-PCR-confirmed A(H1N1)pdm09 was 1.71 (95% CI, 0.78-3.73) in LAIV versus IIV recipients.
Conclusions:
LAIV and IIV demonstrated effectiveness against any influenza among children aged 2-17 years in 2015-2016. When compared to all unvaccinated children, VE against influenza A(H1N1)pdm09 was significant for IIV but not LAIV.
ClinicalTrials.gov identifier:
NCT01997450.
KEYWORDS:
children; influenza; influenza vaccine; vaccine effectiveness
PMID: 29029064 DOI: 10.1093/cid/cix869